{
  "docId": "019de074-80bf-72b8-b7b1-d0f771f9e60f",
  "docSlug": "78e7004510e3b27003e9c94a6172e682",
  "documentTitle": "Chimerix | Investor Presentation Deck | 38 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 38,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-80bf-72b8-b7b1-d0f771f9e60f/22",
  "deckHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f",
  "deckJsonHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f.json",
  "deckAnchorHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.8,
        "x": 0.08,
        "y": 0.575
      },
      "kind": "list",
      "text": "No effective alternative therapies\nHigh unaided awareness among neuro-oncologists\nMutation routinely identified by existing diagnostics\nLonger-term, potentially combinable with other glioma therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09214136-b041-4f25-94fc-22853390d1a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.06,
        "y": 0.18
      },
      "kind": "list",
      "text": "No approved therapies for H3 K27M mutant glioma, ONC201 is the leading program targeting this mutation globally\nPotential market opportunity ~$750 million\nApproximately 5,000 patients in top seven markets\nUltra-orphan indication drug pricing\nH3 K27M mutations most often in children / young adults (little to no exposure to Medicare)\nLow barriers to adoption\nPatent protection for lead indication into 2037 - potential U.S. patent term extension (up to five years)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "698f69ce-b41e-4335-8b68-f236c51b57f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.06,
        "y": 0.06
      },
      "kind": "title",
      "text": "H3 K27M-mutant glioma: rapid ramp to peak revenue expected",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d60430f-4c32-479b-9761-81fea711b43a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "d20789ad-851b-4bd3-a77a-2d3b8a0abaa8",
      "evidence": "The slide provides market sizing information and potential market opportunity.",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}